|
|
Post by mango on Jan 13, 2023 6:56:16 GMT -5
“And then they have an option to license a second product if they want on our platform. They have exclusivity for PAH. And so they are looking for other assets to continue to grow in the inhalation space. As you heard, they're very happy. We've been a great partner. They've been a great partner, and we hope to be able to find more assets to help more patients in this disease.“
|
|
|
|
Post by akemp3000 on Jan 13, 2023 7:08:13 GMT -5
I wonder if anybody at JPM took note of Mike's mention of our eventual need for an Asia/Pacific partner. Negotiating mergers and contracts is what they do, I believe. Man, to be a fly on the wall.... Now, I wonder if THAT isn't why they invited us to speak today. Yes. This jumped out at me also. I believe he said Mannkind would be going it alone in the U.S. but internationally will require partners, especially in the Asia/Pacific market where the potential is much, much larger. He specifically mentioned Japan. I don't recall which drug he was referring to about this so the transcript needs to be reviewed. Anyone? |
|
|
|
Post by akemp3000 on Jan 13, 2023 7:22:35 GMT -5
Years ago, many of us believed Mannkind might eventually become one of the largest drug companies in the world based on the scientifically advanced Technosphere. Hopes for this have been crushed again and again with the challenges, road blocks, and lack of money. MC's presentation at J.P. Morgan had a much more global perspective than seen previously emphasizing the expanding pipeline and discussing global events and opportunities. He even mentioned twice that pipeline development is happening "much faster now". Granted fast in the biotech world means "glacial speed". The company's future looks brighter with the presentation. Maybe, just maybe?
|
|
|
|
Post by Clement on Jan 13, 2023 7:56:51 GMT -5
At about 840 in the Mannkind presentation he talks about United going into IPF and the expansion of 125k patients. The manufacturing building expansion is being funded by United to be ready for IPF. Probably a 7-10 billion plus expansion of Tyvaso in a new market in 2025. That could be a royalty/manufacturing amount of up to 2 billion for Mannkind. Wow. This does not include the second product that Mike breezed over. Quick edit: Mannkind will compete directly with Tyvaso with Nintedenib DPI. Under the idea they can dose much higher than oral and go directly into the lungs. Let's see who wins! 2 agrees and a comment: 1) "up to 2 billion for Mannkind. Wow." !! 2) "Mannkind will compete directly with Tyvaso with Nintedenib DPI." IDK what MNKD and UTHR have planned here. But the Teton study allows stacking of Tyvaso on top of nintedanib for existing nintedanib users. Slide 18 of UTHR presentation for the JPM conference. s1.q4cdn.com/284080987/files/doc_downloads/2023/01/2023-01-09-JPM-preso-FINAL.pdf |
|
|
|
Post by Clement on Jan 13, 2023 8:08:24 GMT -5
I wonder if anybody at JPM took note of Mike's mention of our eventual need for an Asia/Pacific partner. Negotiating mergers and contracts is what they do, I believe. Man, to be a fly on the wall.... Now, I wonder if THAT isn't why they invited us to speak today. Yes. This jumped out at me also. I believe he said Mannkind would be going it alone in the U.S. but internationally will require partners, especially in the Asia/Pacific market where the potential is much, much larger. He specifically mentioned Japan. I don't recall which drug he was referring to about this so the transcript needs to be reviewed. Anyone? Clofazimine --- NTM Slide 14 of MNKD presentation at JPM conference investors.mannkindcorp.com/static-files/533c26ae-732c-40c7-8229-8c943857fe63 |
|
|
|
Post by sayhey24 on Jan 13, 2023 8:48:36 GMT -5
What I heard during the presentation is Mike said afrezza is for the T1 market and V-Go is now for the T2 market. IMO that is a huge change. While I am not surprised its very sad Mike has thrown in the towel on the $40B T2 market while holding the greatest advance in T2 diabetes care.
|
|
|
|
Post by hellodolly on Jan 13, 2023 9:03:52 GMT -5
What I heard during the presentation is Mike said afrezza is for the T1 market and V-Go is now for the T2 market. IMO that is a huge change. While I am not surprised its very sad Mike has thrown in the towel on the $40B T2 market while holding the greatest advance in T2 diabetes care. It appears that Mike has the team focused on a very different path to profitability than what investors have in mind. Who knows, maybe it will become a priority (or a need) in the coming years. With that said, it's time to look forward to all of the other existing opportunities that lay ahead in the immediate future. I'm not going to be stuck on only one path to profitability as it is clear he has a strategy which he thinks is viable given the current climate at the FDA, their cash on hand, current pipeline and commitment to the existing goals. |
|
|
|
Post by cretin11 on Jan 13, 2023 9:17:50 GMT -5
What I heard during the presentation is Mike said afrezza is for the T1 market and V-Go is now for the T2 market. IMO that is a huge change. While I am not surprised its very sad Mike has thrown in the towel on the $40B T2 market while holding the greatest advance in T2 diabetes care. You are more knowledgeable than me about this, but possibly is Afrezza not as good as we thought and VGo is better for T2s? |
|
|
|
Post by sayhey24 on Jan 13, 2023 9:43:51 GMT -5
What I heard during the presentation is Mike said afrezza is for the T1 market and V-Go is now for the T2 market. IMO that is a huge change. While I am not surprised its very sad Mike has thrown in the towel on the $40B T2 market while holding the greatest advance in T2 diabetes care. You are more knowledgeable than me about this, but possibly is Afrezza not as good as we thought and VGo is better for T2s? What is Mike using himself? Is Mike using afrezza or V-Go? Al Mann developed afrezza for T2s not T1s. Al thought he had the greatest advance in T2 care since Banting and Best and put $1B of his own money into this. Overall MNKD has $3B invested in it. Afrezza can stop T2 progression. Nothing is better for T2 glucose control. It even works great when teamed with GLP1s which are primarily being used to target weight loss. The problem is Mike doesn't know how to sell into the T2 market. His approaches to date have failed. Its a $40B market and Big Pharma doesn't want afrezza disrupting it. If you prescribe afrezza first there is a great chance most progression will stop. If so you don't need the GLP1s, DDP4s, SGLT2, etc. Afrezza would destroy this market for BP. It would also destroy the ADA as most of their funding will dry up. IMO Mike is being very risk averse and at this point is giving up on the T2s and just going after the low hanging fruit with the kids in the T1 market. This is where Mike and I have a a huge disagreement. At the same time we know BP will do whatever they need to do to destroy MNKD if it goes after this market. We have seen that for 14+ years. At this point I would say Mike is a bit spooked. Mike tried his "seeing if believing" campaign and failed. He said they spend $6M in about 3 months. I have no idea what they did, why it failed or how they could have spend $6M in 3 months. BTW - the V-Go market is primarily for the T2 medicare market which can now get afrezza for $35. With V-Go they will have to pay about 20% for the device and then the $35 for the RAA to put in it. Afrezza would not only be cheaper but would also provide better control and a hell of a lot less work for the T2. |
|
|
|
Post by akemp3000 on Jan 13, 2023 9:57:37 GMT -5
No way. Mike has not thrown in the towel at all nor is Afrezza not as good as thought. Review the transcript carefully. He overhauled the business plan several years ago based on insufficient funding at the time to try to disrupt a hundred years of the giant diabetes industry. Continuing investments down that path would have bankrupted the company. His revised business plan transitioned the company to instead focus on expanding the developmental pipeline to pursue orphan drug opportunities and unmet needs. This was a more realistic and strategic path to bring in life saving funds quicker, which is exactly what is happening. While there's still a focus on Afrezza, especially with pediatrics, the focus will increase at such time it makes better financial sense to battle the giant diabetes cartel. Hopefully this begins sooner rather than later but only with a lot more funding or if a partner comes to the game. I agree the current status of Afrezza is frustrating but hearing the J.P. Morgan presentation, MC now has this company heading in a very good direction. IMO this is the bigger picture.
|
|
|
|
Post by sportsrancho on Jan 13, 2023 10:59:51 GMT -5
Well, then he better give guidance because if he doesn’t know where the companies going, who will!
Stock needs to hold above $5
|
|
|
|
Post by mymann on Jan 13, 2023 12:35:02 GMT -5
Unth sp dropped after JPM presentation and mnkd is doing the same. Good news don't seem to matter anymore.
|
|
|
|
Post by sr71 on Jan 13, 2023 13:20:15 GMT -5
Unth sp dropped after JPM presentation and mnkd is doing the same. Good news don't seem to matter anymore. Yes, I noticed those drops too. My current theory is that the (trapped?) MNKD shorts are engineering its drop in what could be one of the last chances to unwind a significant chunk of the 29+ million short shares reported as of 12/30/22. Other concerning risk factors are also threatening the overall markets: Inflation, the Fed, possible recession, the deficit, debt ceiling, political turmoil at home and around the world, etc. . . . As for UTHR's drop, who knows? |
|
|
|
Post by mymann on Jan 13, 2023 13:28:30 GMT -5
Unth sp dropped after JPM presentation and mnkd is doing the same. Good news don't seem to matter anymore. Yes, I noticed those drops too. My current theory is that the (trapped?) MNKD shorts are engineering its drop in what could be one of the last chances to unwind a significant chunk of the 29+ million short shares reported as of 12/30/22. Other concerning risk factors are also threatening the overall markets: Inflation, the Fed, possible recession, the deficit, debt ceiling, political turmoil at home and around the world, etc. . . . As for UTHR's drop, who knows? GS came out with UTHR price target of $240 before Christmas week. I thought those guys were attacking UTHR to indirectly trying to keep Mnkd sp below $5. Just my neive opinion. |
|
|
|
Post by tarheelblue004 on Jan 13, 2023 14:57:50 GMT -5
akemp3000 , I don't think you understand. Everything bad that happens to MannKind is Mike's fault. Everything good that happens is thanks to Martine, Al, or pure luck. Once you realize this, you will stop writing such reasonable summaries of information that was provided yesterday. You'll realize that Mike hasn't transformed the cash position, revenue diversity, growth rate or pipeline of MannKind over the past 5 years. He definitely hasn't done his one single job he was hired to do of selling Afrezza during the global pandemic, going up against an oligopoly of BP companies and doctor's habits without the right trial data. Did I mention GLP, Type 2 strategy, V-Go being a terrible acquisition, and that the shorts are not trapped? You will learn akemp 
|
|
